SEC Form 4 · accession 0000939767-16-000241
EXELIXIS, INC. · EXEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gisela Schwab
Officer — Pres Prod Dev & Med Aff & CMO
Period of report
Aug 31, 2016
Accepted (ET)
Sep 2, 2016 · 4:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000939767
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 31, 2016 | M | 132,662 | $9.73 | A | 267,596 | D | |
| Common StockF3 | Aug 31, 2016 | S | 131,155 | $10.98 | D | 136,441 | D | |
| Common StockF4 | holding | — | — | — | 13,806 | I | By 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F5 | $9.73 | Aug 31, 2016 | M | 132,662 | D | Sep 1, 2007 | Aug 31, 2016 | Common Stock | 132,662 | 0 | D |
Explanation of responses
- F1Includes 2,918 shares of common stock acquired pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan.
- F2The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2016.
- F3Represents the weighted average purchase price. The shares were sold in multiple transactions at prices ranging from $10.91 to $11.07. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
- F4Represents 13,806 shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of August 31, 2016.
- F5The option, representing the right to purchase a total of 175,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 1, 2010.